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of diabetic patients enrolled. Ours was a prospective randomized
study. By randomizing the patients prior to their procedure, the
possibility of bias was negated. As noted in our Table 1, no
significant differences existed between groups in any patient
characteristic (including cardioplegia type, diabetes, and beta-
blocker use) (3).
Both groups demonstrated an equal number of diabetics, use of
beta-blockers, and cold or warm blood cardioplegia. Therefore, the
differences between the groups seen at the conclusion of the study
cannot be attributed to any of these factors. As Dr. Bisleri and
colleagues state, there was an equal number of diabetics in both
groups (35% vs. 31%; p  NS) (3). Although this number of
diabetic patients is higher than expected for the general popula-
tion, we were evaluating bypass patients in whom a higher
incidence of diabetes is expected. As there were no significant
differences in the patient characteristics, the effect on atrial
fibrillation seen at the conclusion of the study is separate and
significant.
Finally, the concern that “off-pump” bypass surgery decreases a
“well-known” risk of atrial fibrillation is relevant to our study.
During “off-pump” bypass, there is no cross-clamp applied, and
minimal if any anterior fat pad dissection occurs. We agree that
this may be one of the factors reducing the risk of atrial fibrillation
using this approach.
In summary, the prospective randomized design of our study
should address the concerns of Dr. Bisleri and colleagues. We
agree that this study generates many questions regarding the
mechanism of postoperative atrial fibrillation, and we look forward
to future studies. The reality is that the sample size was small and
although the patients were randomized, dogmatic conclusions are
not warranted, at least not yet.
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Cardiac Complications of Vaccines
We read with interest the recent study by Eckart et al. (1) entitled
“Incidence and Follow-Up of Inflammatory Cardiac Complica-
tions After Smallpox Vaccination.” Although smallpox is the most
common vaccine that is associated with myocarditis, other vaccines
have also been linked with myocarditis, such as diphtheria–
tetanus–polio vaccine, tetanus vaccine alone, cholera, typhoid–
cholera, and variola vaccines (2–6). In order to assess any relation-
ship between smallpox vaccination and myocarditis more
accurately, it would be essential to know what other vaccines were
administered to the military personnel in the study. Moreover, was
there any relationship between specific lot numbers and myocarditis?
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REPLY
We appreciate the comments of Dr. Kula and colleagues regarding
our publication on vaccinia-associated myocarditis (1). We agree
with the need to consider the possible contributions of other
vaccinations to myocarditis, and we recognize the potential for
confounding. Our group recently published data revealing no
statistically significant association of development of vaccinia-
associated myocarditis in those with concomitant administration of
other vaccines (2). Other vaccines in addition to vaccinia in cases
of myocarditis may have included anthrax, typhoid, hepatitis A,
hepatitis B, influenza, meningococcal, MMR (measles, mumps,
rubella), poliovirus, and yellow fever vaccines. No association was
seen between specific lot numbers and development of myocarditis.
We note that all the available references cited by Kula and
colleagues were isolated case reports relating to other vaccines
(3–6). Although they raise interesting questions, the reported
observations are less persuasive than the extended case series we
have reported (1,2). Recognizing that our experience is not within
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the context of a prospective trial, we cannot exclude the possibility
of multiple vaccine interactions; however, it appears unlikely at this
time.
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A Simple, Inexpensive, Rapid,
and Accurate Preclinical
Model for In-Stent Restenosis
With great interest we read the recent review by Schwartz et al. (1)
regarding preclinical animal restenosis models. Detailed descrip-
tions of the current available animal restenosis models, the patho-
physiology of in-stent restenosis (ISR), and the usefulness of
animal restenosis models to predict clinical outcomes are pre-
sented. In the final remarks it is concluded that preclinical models
are important but imperfect standards. A simple, inexpensive,
rapid, and accurate preclinical model would be useful. However, in
their description of available restenosis models, Schwartz et al. (1)
overlooked two important and recently developed animal models
of ISR. In these models, stents are implanted in the carotid artery
(2) or in the abdominal aorta (3) of the rat. Pathophysiological
processes of neoinitmal formation, such as thrombus formation,
inflammation, and smooth muscle cell proliferation, evolve in an
identical manner as seen in the rabbit iliac and pig coronary artery
models. Moreover, in the rat abdominal aorta model, a positive
correlation is found between the mean injury score and the
neointimal area (2,3).
Rat ISR models enable thorough pathophysiological studies, as
many antibodies to cellular proteins are available in the rat as
compared to rabbits and pigs. By elucidation of the pathophysiol-
ogy of ISR, more purposeful experiments to prevent ISR can be
carried out. Rat models of ISR could provide important indications
for the development of new anti-restenotic strategies (3). Gener-
ally, rat studies are preferable over rabbit or pig studies; only
mainstream surgical equipment is required, animal facilities have
large housing capacity for rats, and the costs for purchase are low.
Discrepancies between efficacy of anti-restenotic agents in
preclinical and clinical studies have caused skepticism about the rat
carotid artery model. For rat stent models this skepticism should be
tempered, because differences in pathophysiological mechanisms
between neointimal formation after balloon dilation alone and
stent implantation are evident. Furthermore, rapamycin-eluting
stents have been shown to inhibit neointimal formation in the rat
abdominal aorta, a clear relation between preclinical and clinical
outcomes in this model (3). In addition, these rat models enable
stent research in transgenic diabetic and hypertensive strains. This
offers a truer reflection of clinical settings in preclinical experi-
ments, and might result in a better prediction of efficacy of
anti-restenotic agents in clinical trials (2,3).
In conclusion, rat models are simple, inexpensive, rapid, and
accurate preclinical models for ISR.
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We read with interest the comments of Dr. Langeveld and
colleagues concerning our recent review of preclinical restenosis
models (1). These investigators write that stenting the rat carotid
or abdominal artery provides a “simple, inexpensive, rapid, and
accurate preclinical model for in-stent restenosis.” We have several
comments in response regarding the utility of the rat model.
A useful in-stent restenosis animal model should accurately
predict: 1) safety, 2) efficacy, and 3) pathophysiologic mechanisms.
These are addressed as follows.
Safety. The major safety issues for stents are thrombosis (acute
or subacute) and neointimal thickening causing luminal stenosis.
Although the rat model sometimes induces stent thrombosis, it
does so to a lesser extent than the porcine and rabbit models. Total
occlusion and severe stent stenosis do not generally occur in the rat
model.
Efficacy. Rat carotid restenosis models were abandoned years ago
because virtually all therapies that were tested and effective in rats
later proved ineffective in patients. Such studies included
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